WordNet

determine the sum of; "Add all the people in this town to those of the neighboring town" (同)tot, tot up, sum, sum_up, summate, tote up, add, add together, tally, add up
damage beyond the point of repair; "My son totaled our new car"; "the rock star totals his guitar at every concert"
add up in number or quantity; "The bills amounted to $2,000"; "The bill came to $2,000" (同)number, add up, come, amount
that part of the ovary of a flowering plant where the ovules form
the vascular structure in the uterus of most mammals providing oxygen and nutrients for and transferring wastes from the developing fetus
a small amount (especially of a drink); "a tot of rum"
used of automobiles; completely demolished; "the insurance adjuster declared the automobile totaled"

PrepTutorEJDIC

『総計の』,全体の / 『全くの』,完全な(absolute) / 『合計』,総額,総数,総量(sum) / …‘を'合計する / 合計…‘に'なる,総額が…‘に'のぼる(amount to)
胎盤
幼児,小児 / (特に酒類の)少量,一杯,一口
…‘を'合計する《+up+名,+名+up》 / 合計(…に)なる《+up to+名》

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 前置胎盤のマネージメント management of placenta previa
2. 前置胎盤の臨床的特徴、診断、および経過 clinical features diagnosis and course of placenta previa
3. 癒着胎盤、嵌入胎盤、および穿通胎盤のマネージメント management of placenta accreta increta and percreta
4. 妊産婦の施設間搬送 inter facility maternal transport
5. 癒着胎盤、嵌入胎盤、および穿通胎盤の臨床的特徴および診断 clinical features and diagnosis of placenta accreta increta and percreta

English Journal

A comparison of oxytocin and carboprost tromethamine in the prevention of postpartum hemorrhage in high-risk patients undergoing cesarean delivery.

Bai J, Sun Q, Zhai H.Author information Department of Gynecology and Obstetrics, Jinan Maternity and Child Care Hospital, Jinan, Shandong 250001, P.R. China.AbstractThe aim of this study was to compare carboprost with oxytocin for the prevention of postpartum hemorrhage (PPH) in females with a high risk of PPH undergoing cesarean delivery. Patients were randomly divided into three groups that received different uterotonics (oxytocin, carboprost and oxytocin plus carboprost) during cesarean section, following the delivery of the infant. A total of 117 females (age range, 19-40 years) at 35-40 weeks gestation who delivered by cesarean between December, 2010 and May, 2012 were included in this study. There were 29 cases of twins, 12 cases of polyhydramnios, 23 cases of placenta previa and 53 cases of fetal macrosomia. There were 37 patients in the oxytocin group, 36 in the carboprost group and 44 in the oxytocin plus carboprost group. No significant differences were identified in maternal age, gravidity/parity, gestational age and reason for cesarean delivery between the three groups. The median blood loss in the oxytocin, carboprost and oxytocin plus carboprost groups was 610, 438 and 520 ml, respectively. The blood loss in the carboprost group was significantly lower than that in the oxytocin and oxytocin plus carboprost groups (both P<0.05). Vomiting occurred in eight patients from the carboprost group, two from the oxytocin group and two from the oxytocin plus carboprost group (P=0.036). Carboprost was more effective than oxytocin in preventing PPH in high-risk patients undergoing cesarean delivery.
Experimental and therapeutic medicine.Exp Ther Med.2014 Jan;7(1):46-50. Epub 2013 Nov 1.
The aim of this study was to compare carboprost with oxytocin for the prevention of postpartum hemorrhage (PPH) in females with a high risk of PPH undergoing cesarean delivery. Patients were randomly divided into three groups that received different uterotonics (oxytocin, carboprost and oxytocin plu
PMID 24348762

Natural history of vasa previa across gestation using a screening protocol.

Rebarber A, Dolin C, Fox NS, Klauser CK, Saltzman DH, Roman AS.Author information Maternal-Fetal Medicine Associates, PLLC, 70 East 90th St, New York, NY 10128 USA. arebarber@mfmnyc.com.AbstractObjectives- The purpose of this study was to estimate the prevalence and persistence rate of vasa previa in at-risk pregnancies using a standardized screening protocol. Methods- We conducted a descriptive study of patients with a diagnosis of vasa previa from a single ultrasound unit between June 2005 and June 2012. Vasa previa was defined as a fetal vessel within 2 cm of the internal cervical os on transvaginal sonography. Screening for vasa previa using transvaginal sonography with color flow mapping was performed routinely in the following situations: resolved placenta previa, prior pregnancy with vasa previa, velamentous insertion of the cord in the lower uterine segment, placenta succenturiata in the lower uterine segment, and twin gestations. Results- A total of 27,573 patients were referred to our unit for fetal anatomic surveys over the study period. Thirty-one cases of vasa previa were identified, for an incidence of 1.1 per 1000 pregnancies. Twenty-nine cases had full records available for analysis. Five patients (17.2%) had migration and resolution of the vasa previa. When the diagnosis was made during the second trimester (<26 weeks), there was a 23.8% resolution rate (5 of 21); when the diagnosis was made in the third trimester, none resolved (0 of 8 cases). Of the 24 pregnancies (5 twin gestations and 19 singleton gestations) with persistent vasa previa, there was 100% perinatal survival and a median length of gestation of 35 weeks (range, 27 weeks 5 days-36 weeks 5 days). No known missed cases were identified over the study period. Conclusions- The use of standardized screening for vasa previa based on focused criteria was found to be effective in diagnosing vasa previa, with a 100% survival rate. Vasa previa diagnosed during the second trimester resolves in approximately 25% of cases.
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.J Ultrasound Med.2014 Jan;33(1):141-7. doi: 10.7863/ultra.33.1.141.
Objectives- The purpose of this study was to estimate the prevalence and persistence rate of vasa previa in at-risk pregnancies using a standardized screening protocol. Methods- We conducted a descriptive study of patients with a diagnosis of vasa previa from a single ultrasound unit between June 20
PMID 24371109